Welcome to the international HTA database

Showing [16381 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2021	National Institute for Health and Care Excellence (NICE)	The VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal. NICE medical technologies guidance 54
2021	Belgian Health Care Knowledge Centre (KCE)	Do innovative medicines against cancer always have a real added value?
2021	National Institute for Health and Care Excellence (NICE)	The PLASMA system for transurethral resection and haemostasis of the prostate. NICE medical technologies guidance 53
2021	Agency for Healthcare Research and Quality (AHRQ)	Maternal, fetal, and child outcomes of mental health treatments in women: a systematic review of perinatal pharmacologic interventions
2021	NIHR Health Technology Assessment programme	Prognostic tools for identification of high risk in people with Crohn’s disease: systematic review and cost-effectiveness study
2021	NIHR Health Technology Assessment programme	Thoracoscopic surgical ablation versus catheter ablation as first-line treatment for long-standing persistent atrial fibrillation: the CASA-AF RCT
2021	Scottish Medicines Consortium (SMC)	Afamelanotide (Scenesse) for prevention of photoxicity in adult patients with erythropoietic protoporphyria (EPP)
2021	Scottish Medicines Consortium (SMC)	Upadacitinib for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs)
2021	NIHR Health Technology Assessment programme	Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study
2021	Scottish Medicines Consortium (SMC)	Ravulizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): in patients with haemolysis with clinical symptom(s) indicative of high disease activity; in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months
2021	NIHR Health Technology Assessment programme	Facilitating the return to work of NHS staff with common mental health disorders: a feasibility study
2021	Scottish Medicines Consortium (SMC)	Ozanimod for adult patients with relapsing remitting multiple sclerosis
2021	NIHR Health Technology Assessment programme	A prognostic model, including quantitative fetal fibronectin, to predict preterm labour: the QUIDS meta-analysis and prospective cohort study
2021	Scottish Medicines Consortium (SMC)	Entrectinib as monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion: who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity; and who have not received a prior NTRK inhibitor; who have no satisfactory treatment options
2021	NIHR Health Technology Assessment programme	Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT
2021	NIHR Health Technology Assessment programme	Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT
2021	Scottish Medicines Consortium (SMC)	Onasemnogene abeparvovec treatment of patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene
2021	Agency for Healthcare Research and Quality (AHRQ)	Physical activity and the health of wheelchair users: a systematic review in multiple sclerosis, cerebral palsy, and spinal cord injury
2021	Scottish Health Technologies Group (SHTG)	NHSScotland COPD Support Service: remote and self-management of high-risk patients with COPD using a web app and machine learning predictive modelling
2021	Agency for Healthcare Research and Quality (AHRQ)	Prehabilitation and rehabilitation for major joint replacement
2021	Agency for Healthcare Research and Quality (AHRQ)	Prehospital airway management
2021	Agency for Healthcare Research and Quality (AHRQ)	Radiation therapy for brain metastases
2021	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Lipoedema – diagnosis, treatment, and experiences]
2021	NIHR Public Health Research (PHR) programme	School-based interventions to prevent anxiety, depression and conduct disorder in children and young people: a systematic review and network meta-analysis
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Opioid pain assessment
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Effectiveness of intra-operative antimicrobial irrigation to prevent surgical site infection in clean surgeries
2021	Agency for Healthcare Research and Quality (AHRQ)	Safety of vaccines used for routine immunization in the United States: an update
2021	NIHR Health Technology Assessment programme	The Arabin pessary to prevent preterm birth in women with a twin pregnancy and a short cervix: the STOPPIT 2 RCT
2021	NIHR Public Health Research (PHR) programme	A school-based, peer-led programme to increase physical activity among 13- to 14-year-old adolescents: the GoActive cluster RCT
2021	Agency for Care Effectiveness (ACE)	Rituximab for treating non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Robotics and functional electrical stimulation for stroke rehabilitation: systematic review
2021	Austrian Institute for Health Technology Assessment (AIHTA)	[Parent-Child-Pass Update 2020/21 – Screenings for mental health, nutrition and social competence]
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Ambulatory blood glucose checks
2021	Agency for Care Effectiveness (ACE)	Tenofovir alafenamide for treating chronic hepatitis B infection
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Prevention of opioid-induced respiratory depression (OIRD) in hospital care
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Bedaquiline (new therapeutic indication: pulmonary multidrug-resistant tuberculosis, 5 to 11 years)]
2021	Agency for Care Effectiveness (ACE)	Metformin extended release for treating type 2 diabetes mellitus
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Ventral rectopexy for the treatment of rectal prolapse and intussusception
2021	NIHR Health Technology Assessment programme	Social recovery therapy for young people with emerging severe mental illness: the Prodigy RCT
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Fall prevention in ambulatory care facilities
2021	Agency for Care Effectiveness (ACE)	Guselkumab, ixekizumab and secukinumab for treating chronic plaque psoriasis
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Endoscopic sleeve gastroplasty for the treatment of patients with Class I and II obesity who have failed first-line (lifestyle modification) and second-line (VLED/pharmacotherapy) treatments
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Triaging COVID-19 in the emergency department
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Belantamab mafodotin (multiple myeloma, at least 4 prior therapies, monotherapy)]
2021	Agency for Care Effectiveness (ACE)	Ixekizumab and secukinumab for treating active psoriatic arthritis
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Permanent acute coronary syndrome event detector (insertion, removal or replacement of) for monitoring of the heart's electrical activity
2021	National Institute for Health and Care Excellence (NICE)	SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea. NICE diagnostics guidance 44
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Critical value thresholds
2021	Agency for Care Effectiveness (ACE)	Dacomitinib for treating EGFR mutation-positive non-small-cell lung cancer
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Modification of the wording of minimally invasive glaucoma surgery (MIGS) existing item number to encompass the use of a microcatheter
2021	National Institute for Health and Care Excellence (NICE)	QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography. NICE diagnostics guidance 43
2021	Health Technology Wales (HTW)	Corneal crosslinking to treat adults and children with keratoconus
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Benefit assessment of medicinal products with new active ingredients according to section 35a SGB V: Blinatumomab (new therapeutic indication: B-precursor acute lymphoblastic leukaemia, relapsed or refractory, Ph+ CD19+)]
2021	Agency for Care Effectiveness (ACE)	Ixekizumab and secukinumab for treating active ankylosing spondylitis
2021	Agency for Healthcare Research and Quality (AHRQ)	Treatments and technologies supporting appropriate opioid tapers
2021	Health Technology Wales (HTW)	Freestyle Libre flash glucose monitoring for the management of diabetes
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Bulevirtide (chronic hepatitis delta virus (HDV) infection)]
2021	Agency for Healthcare Research and Quality (AHRQ)	Treatments, technologies, and models for management of acute and chronic pain in people with a history of substance use disorder
2021	NIHR Health Technology Assessment programme	Estimating the benefits and harms of Z-drugs for people with dementia and sleep disorders
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Afamelanotide (Reassessment after the deadline: Phototoxicity in erythropoietic protoporphyria (EPP))]
2021	NIHR Health Technology Assessment programme	Preventing enduring behavioural problems in young children through early psychological intervention: Healthy Start, Happy Start
2021	Norwegian Institute of Public Health (NIPH)	Minimally invasive glaucoma surgery (MIGS) for individuals with glaucoma. A health technology assessment
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Crizanlizumab (repeal of the resolution of 20 May 2021)]
2021	NIHR Health Technology Assessment programme	Statin Web-based Investigation of Side Effects Trial (Statin WISE Trial)
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Fedratinib (myelofibrosis)]
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Modification of the wording of minimally invasive glaucoma surgery (MIGS) existing item number to encompass the use of a microcatheter
2021	NIHR Health Technology Assessment programme	Prognostic indicators of severe disease in late preterm pre-eclampsia to guide decision making on timing of delivery: the PEACOCK study
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Fenfluramine (Dravet syndrome, ≥ 2 years)]
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Alpha-1 antitrypsin genotyping
2021	NIHR Health Technology Assessment programme	A randomized controlled trial to study the effectiveness of laser ablation versus observation to prevent anal cancer in men with human immunodeficiency virus who have high-grade anal intraepithelial neoplasia
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Streamlining Medicare Benefits Schedule items for positron emission tomography (PET) project
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Glasdegib (acute myeloid leukaemia (AML), combination with cytarabine (LDAC))]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Imlifidase (desensitisation in kidney transplantation)]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ivacaftor/Tezacaftor/Elexacaftor (Exceeding the € 50 Million Limit, Cystic Fibrosis, Combination Treatment with Ivacaftor in Patients 12 Years and Older (Heterozygous for F508del and MF Mutation))]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ivacaftor/Tezacaftor/Elexacaftor (exceeding the € 50 million limit, cystic fibrosis, combination treatment with Ivacaftor in patients 12 years and older (homozygous for F508del mutation))]
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Lumasiran (Hyperoxaluria)]
2021	NIHR Health Services and Delivery Research programme	Progressive exercise compared with best-practice advice, with or without corticosteroid injection, for rotator cuff disorders: the GRASP factorial RCT
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Luspatercept (Myelodysplastic Syndrome (MDS))]
2021	Malaysian Health Technology Assessment (MaHTAS)	Hyperthermic intraperitoneal chemotherapy as an adjuvant therapy for peritoneal surface malignancy (PSM)
2021	NIHR Public Health Research (PHR) programme	Does slip resistant footwear reduce slips among healthcare workers? A randomised controlled trial
2021	National Institute for Health and Care Excellence (NICE)	Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer. NICE technology appraisal guidance 668
2021	NIHR Health Technology Assessment programme	Tranexamic acid to reduce head injury death in people with traumatic brain injury: the CRASH-3 international RCT
2021	NIHR Health Technology Assessment programme	Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Artificial intelligence in surgery and surgical education
2021	National Institute for Health and Care Excellence (NICE)	Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor. NICE technology appraisal guidance 670
2021	Swiss Federal Office of Public Health (FOPH)	Long-term physiotherapy in patients after stroke, with multiple sclerosis, or with Parkinson’s disease
2021	National Institute for Health and Care Excellence (NICE)	Mepolizumab for treating severe eosinophilic asthma. NICE technology appraisal guidance 671
2021	NIHR Public Health Research (PHR) programme	An online family-based self-monitoring and goal-setting intervention to improve children’s physical activity: the FRESH feasibility trial and three-arm pilot RCT
2021	National Institute for Health and Care Excellence (NICE)	Brolucizumab for treating wet age-related macular degeneration. NICE technology appraisal guidance 672
2021	National Institute for Health and Care Excellence (NICE)	Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 673
2021	National Institute for Health and Care Excellence (NICE)	Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal). NICE technology appraisal guidance 674
2021	National Institute for Health and Care Excellence (NICE)	Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal). NICE technology appraisal guidance 675
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Luspatercept (β-thalassaemia)]
2021	National Institute for Health and Care Excellence (NICE)	Filgotinib for treating moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 676
2021	National Institute for Health and Care Excellence (NICE)	Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma. NICE technology appraisal guidance 677
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Effectiveness and safety of vitamin B12 tests
2021	National Institute for Health and Care Excellence (NICE)	Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal). NICE technology appraisal guidance 678
2021	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Osilodrostat (Endogenous Cushing’s Syndrome)]
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Long-term physiotherapy in patients after stroke, with multiple sclerosis, or with Parkinson's disease
2021	National Institute for Health and Care Excellence (NICE)	Dapagliflozin for treating chronic heart failure with reduced ejection fraction. NICE technology appraisal guidance 679